Natixis Advisors LLC Purchases 2,033 Shares of Humana Inc. $HUM

Natixis Advisors LLC increased its position in shares of Humana Inc. (NYSE:HUM) by 3.7% during the 4th quarter, according to its most recent filing with the Securities and Exchange Commission (SEC). The fund owned 57,656 shares of the insurance provider’s stock after acquiring an additional 2,033 shares during the quarter. Natixis Advisors LLC’s holdings in Humana were worth $14,767,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also bought and sold shares of HUM. Montag A & Associates Inc. boosted its stake in Humana by 1,880.0% during the 4th quarter. Montag A & Associates Inc. now owns 99 shares of the insurance provider’s stock worth $25,000 after acquiring an additional 94 shares during the last quarter. CoreCap Advisors LLC boosted its stake in Humana by 54.4% during the 4th quarter. CoreCap Advisors LLC now owns 105 shares of the insurance provider’s stock worth $27,000 after acquiring an additional 37 shares during the last quarter. Fideuram Asset Management Ireland dac bought a new position in Humana during the 4th quarter worth approximately $27,000. Rosenberg Matthew Hamilton boosted its stake in Humana by 136.0% during the 4th quarter. Rosenberg Matthew Hamilton now owns 118 shares of the insurance provider’s stock worth $30,000 after acquiring an additional 68 shares during the last quarter. Finally, Larson Financial Group LLC boosted its stake in Humana by 114.1% during the 3rd quarter. Larson Financial Group LLC now owns 152 shares of the insurance provider’s stock worth $40,000 after acquiring an additional 81 shares during the last quarter. Institutional investors own 92.38% of the company’s stock.

Humana Stock Up 0.0%

HUM stock opened at $349.85 on Friday. The company has a debt-to-equity ratio of 0.66, a current ratio of 1.77 and a quick ratio of 1.77. The stock has a market capitalization of $42.00 billion, a P/E ratio of 37.42, a P/E/G ratio of 2.00 and a beta of 0.76. The business has a 50-day moving average of $248.43 and a 200-day moving average of $232.40. Humana Inc. has a fifty-two week low of $163.11 and a fifty-two week high of $351.88.

Humana (NYSE:HUM) last posted its quarterly earnings data on Wednesday, April 29th. The insurance provider reported $10.31 earnings per share for the quarter, topping the consensus estimate of $9.97 by $0.34. The company had revenue of $39.65 billion during the quarter, compared to analysts’ expectations of $39.37 billion. Humana had a return on equity of 10.45% and a net margin of 0.82%.Humana’s revenue for the quarter was up 23.5% compared to the same quarter last year. During the same period in the prior year, the firm earned $11.58 earnings per share. Humana has set its FY 2026 guidance at 9.000- EPS. On average, sell-side analysts anticipate that Humana Inc. will post 9 earnings per share for the current fiscal year.

Humana Dividend Announcement

The firm also recently disclosed a quarterly dividend, which will be paid on Friday, July 31st. Stockholders of record on Friday, June 26th will be given a $0.885 dividend. This represents a $3.54 dividend on an annualized basis and a dividend yield of 1.0%. The ex-dividend date of this dividend is Friday, June 26th. Humana’s payout ratio is currently 37.86%.

Wall Street Analyst Weigh In

Several research analysts recently weighed in on the stock. Barclays lifted their price objective on shares of Humana from $180.00 to $344.00 and gave the stock an “equal weight” rating in a research note on Tuesday, May 26th. TD Cowen lifted their price objective on shares of Humana from $173.00 to $211.00 and gave the stock a “hold” rating in a research note on Friday, May 1st. Bank of America lifted their price objective on shares of Humana from $267.00 to $340.00 and gave the stock a “neutral” rating in a research note on Thursday. Oppenheimer raised shares of Humana from an “outperform” rating to an “outperform” rating in a research note on Wednesday, May 20th. Finally, Cantor Fitzgerald assumed coverage on shares of Humana in a research note on Wednesday, May 20th. They issued an “overweight” rating on the stock. One research analyst has rated the stock with a Strong Buy rating, nine have assigned a Buy rating, fourteen have issued a Hold rating and four have given a Sell rating to the stock. According to MarketBeat.com, the company has an average rating of “Hold” and an average price target of $279.30.

Humana Company Profile

Humana Inc (NYSE: HUM) is a health insurance company headquartered in Louisville, Kentucky, that primarily serves individuals and groups across the United States. The company is best known for its Medicare business, offering Medicare Advantage plans and prescription drug (Part D) coverage, alongside a range of commercial and employer-sponsored group health plans. Humana’s products are designed to cover medical, behavioral health and pharmacy needs for members, with particular emphasis on seniors and Medicare-eligible populations.

In addition to traditional insurance products, Humana provides care-management and wellness services intended to support chronic-condition management, preventive care and care coordination.